News & Updates

Novel tri-agonist confers significant gains for MASLD patients
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023 byAudrey Abella

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023
HBV vaccine improves survival of patients with chronic liver disease
HBV vaccine improves survival of patients with chronic liver disease
22 Nov 2023 byStephen Padilla

Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.

HBV vaccine improves survival of patients with chronic liver disease
22 Nov 2023